Kairos Pharma, LTD. — Form 8-K
Filed July 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Kairos Pharma announced interim Phase 1 safety data for ENV-105 (carotuximab) combined with osimertinib in EGFR-mutated NSCLC: 13 patients treated with no Grade 3+ adverse events observed. ENV-105 targets CD105, a resistance driver in osimertinib-resistant patients. The $10 billion EGFR-NSCLC market has no approved agent to reverse osimertinib resistance; this trial advances toward Phase 2 dose recommendation.
Why this rating
Early safety milestone in lead candidate addresses large unmet need ($10B market). For $6.9M-cap biotech, advancing Phase 1 without safety signals is material. Efficacy data still pending; clinical success far from assured.
See more from July 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.